Jane Osbourn, PhD

CEO at Alchemab Therapeutics

Speaker

Jane is Chief Executive Officer at Alchemab Therapeutics, focussed on understanding the immunological basis of disease resilience, enabling the identification of protective antibodies as therapies for neurodegeneration and oncology. She was an early employee of Cambridge Antibody Technology, which became MedImmune, the biologics arm of AstraZeneca, where she contributed to the development of phage display technology, authored many key publications and patents, and contributed to the discovery and development of eight marketed drugs. Jane is passionate about the development of the biotechnology sector and served as Chair of the UK BioIndustry Association (BIA) from 2015-2019. She is also a founder of RQ Bio, a UK-based infectious disease company focussed on prophylactic antibody therapies, and has been a Director of Cambridge Enterprise, and of Babraham Research Campus. In 2019 Jane was awarded an OBE for services to drug discovery and biotechnology, and in the same year the Scrip Lifetime Achievement Award for contribution to the pharma industry. In 2023 she was awarded the BIA Lifetime achievement award, recognising her sustained contribution to biologics drug development.'